Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results

about

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results

Item

http://www.wikidata.org/entity/Q57108099

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 07 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Dual targeting of HER2-positiv ...... tanding clinical trial results

@en

Dual targeting of HER2-positiv ...... tanding clinical trial results

@nl

type

Item

label

Dual targeting of HER2-positiv ...... tanding clinical trial results

@en

Dual targeting of HER2-positiv ...... tanding clinical trial results

@nl

prefLabel

Dual targeting of HER2-positiv ...... tanding clinical trial results

@en

Dual targeting of HER2-positiv ...... tanding clinical trial results

@nl

P1476

Dual targeting of HER2-positiv ...... tanding clinical trial results

@en

P2093

Atanasio Pandiella

http://www.w3.org/2001/XMLSchema#string

Eitan Amir

http://www.w3.org/2001/XMLSchema#string

P2860

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

HER2: biology, detection, and clinical implications

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.

Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment

Efficacy, safety and administration timing of trastuzumab in human epidermal growth factor receptor 2 positive breast cancer patients: A meta-analysis

Role of trastuzumab in the management of HER2-positive metastatic breast cancer.

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor.

P304

31915-31919

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25739

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Alberto Ocana

P577

2018-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30159132

http://www.w3.org/2001/XMLSchema#string

P932

6112749

http://www.w3.org/2001/XMLSchema#string